Exicure, Inc.

XCUR · Nasdaq · United States

Share price · XCUR

$1.04-0.39 (-27.27%) 3M

close as of 2026-11-18 · 24h delayed · vol 4K (0.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when XCUR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+21.3%
  2. 22 Oct 2026+11.9%
  3. 8 Sep 2026+12.8%
  4. 20 Jul 2026+12.5%

    Nothing announced by XCUR that day or the session before.

  5. 22 Jun 2026+18.6%
  6. 16 Jun 2026-22.2%

    Nothing announced by XCUR that day or the session before.

  7. 4 Jun 2026-6.3%

    Nothing announced by XCUR that day or the session before.

  8. 18 May 2026+7.7%

    Nothing announced by XCUR that day or the session before.

  9. 10 Dec 2025-27.0%

Share of unusual movement by asset

For each asset, the share of XCUR's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Burixafor (TG-0054)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—12%
Other company news (earnings, financing, releases naming no asset)—4%
Sessions with no dated event—85%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
CXCR4Small molecule
Multiple Myeloma

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 December 2025Topline resultBurixafor (TG-0054)Phase 2 of burixafor with propranolol and G-CSF meets primary endpoint in multiple myeloma mobilization
Exicure, Inc. · Source ↗

Financial reports

Quarterly & interim (14)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$0.2M$1.7M$1.1M-$0.9M operating cash flowreport ↗
View 13 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$0$0.3M$2.6M$1.8M-$1.1M operating cash flowreport ↗
2025-Q3—$0.9M$4.4M$2.4M-$3.5M operating cash flowreport ↗
2025-Q2$0$0.9M$7.9M$2.6M-$2.3M operating cash flowreport ↗
2025-Q1$0$0.8M$10M—-$1.6M operating cash flowreport ↗
2024-Q3—$0$0.9M$1.1M-$0.5M operating cash flowreport ↗
2024-Q2—$0$1.4M$0.6M-$1.2M operating cash flowreport ↗
2024-Q1—$0$1.6M$0.8M-$0.5M operating cash flowreport ↗
2023-Q3$0$0$2.1M$5.3M-$1.4M operating cash flowreport ↗
2023-Q2$0$0.9M$3.5M$5.8M-$4.8M operating cash flowreport ↗
2023-Q1$0$2.0M$11M$4.4M-$3.3M operating cash flowreport ↗
2022-Q3$2.0M$4.8M$17M+ $0 short-term inv.$5.2M-$6.5M operating cash flowreport ↗
2022-Q2$2.5M$6.8M$22M+ $1.0M short-term inv.$7.5M-$9.1M operating cash flowreport ↗
2022-Q1$2.6M$7.1M$25M+ $2.5M short-term inv.$8.3M-$13M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$3.3M$3.8M$1.2M-$8.6M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.5M$0$13M$2.4M-$2.9M operating cash flowreport ↗
2023-FY$0$1.4M$2.0M$4.2M-$10M operating cash flowreport ↗
2022-FY$29M$20M$9.8M+ $0 short-term inv.$0.7M-$36M operating cash flowreport ↗
2021-FY-$0.5M$49M$44M+ $4.5M short-term inv.$16M-$35M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 4 sales ($11.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-07-08Exicure HiTron Inc. · 10% ownerOther (see filing)117,441$4.50$528KForm 4
2026-06-26Exicure HiTron Inc. · 10% ownerOther (see filing)253,195$4.50$1.1MForm 4
2026-06-24Exicure HiTron Inc. · 10% ownerOther (see filing)123,456$4.50$556KForm 4
2026-06-23Exicure HiTron Inc. · 10% ownerOther (see filing)129,183$4.50$581KForm 4
2026-02-16Miller Josh · Chief Accounting OfficerTax withholding8$4.08$33Form 4
2026-01-21Exicure HiTron Inc. · 10% ownerOpen-market sale258,367$4.50$1.2MForm 4
2026-01-16Exicure HiTron Inc. · 10% ownerOpen-market sale734,747$4.50$3.3MForm 4
2026-01-07Exicure HiTron Inc. · 10% ownerOpen-market sale741,272$4.50$3.3MForm 4